ProKidney reports a Q2 GAAP loss of $0.15 per share, missing estimates by $0.01, as revenue declines sharply.
ProKidney reported a Q2 GAAP loss of $0.15 per share, wider than the expected $0.14, while revenue of $0.15 million matched estimates but fell 31.8% year-over-year.
The company’s cash reserves totaled $181.6 million as of June 30, 2026, down from $224.9 million at the end of March 2026. Revenue performance aligned with consensus but reflected ongoing declines in core operations.
No immediate market reaction was disclosed in the release.